M
Michihito Sasaki
Researcher at International Institute of Minnesota
Publications - 112
Citations - 2941
Michihito Sasaki is an academic researcher from International Institute of Minnesota. The author has contributed to research in topics: Medicine & Virus. The author has an hindex of 18, co-authored 83 publications receiving 1017 citations. Previous affiliations of Michihito Sasaki include Hokkaido University.
Papers
More filters
Journal ArticleDOI
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
Rigel Suzuki,Daichi Yamasoba,Izumi Kimura,Lei Wang,Mai Kishimoto,Jumpei Ito,Yuhei Morioka,Naganori Nao Nao,Hesham Nasser,Keiya Uriu,Yusuke Kosugi,Masumi Tsuda,Yasuko Orba,Michihito Sasaki,Ryo Shimizu,Ryoko Kawabata,Kumiko Yoshimatsu,Hiroyuki Asakura,Mami Nagashima,Kenji Sadamasu,Kazuhisa Yoshimura,Mai Suganami,Akiko Oide,Mika Chiba,H. Ito,Tomokazu Tamura,Kana Tsushima,Haruko Kubo,Zannatul Ferdous,Hiromi Mouri,Miki Iida,Keiko Kasahara,Koshiro Tabata,Mariko Ishizuka,Asako Shigeno,Kenzo Tokunaga,Seiya Ozono,Iwao Yoshida,So Nakagawa,Jiaqi Wu,Miyoko Takahashi,Atsushi Kaneda,Motoaki Seki,Ryoji Fujiki,Bahityar Rahmutulla Nawai,Yutaka Suzuki,Yukie Kashima,Kazumi Abe,Kiyomi Imamura,Kotaro Shirakawa,Akifumi Takaori-Kondo,Yasuhiro Kazuma,Ryosuke Nomura,Yoshihito Horisawa,Kayoko Nagata,Yugo Kawai,Yohei Yanagida,Yusuke Tashiro,Otowa Takahashi,K. Kitazato,Haruyo Hasebe,Chihiro Motozono,Mako Toyoda,Toong Seng Tan,Isaac Ngare,Takamasa Ueno,Akatsuki Saito,Erika P. Butlertanaka,Yurie Tanaka,Nanami Morizako,Hirofumi Sawa,Terumasa Ikeda,Takashi Irie,Keita Matsuno,Shinya Tanaka,Takasuke Fukuhara,Kei Sato +76 more
TL;DR: The emergence of the Omicron variant of SARS-CoV-2 is an urgent global health concern as mentioned in this paper , and statistical modelling suggests that OmicRON has spread more rapidly than the Delta variant in several countries including South Africa.
Journal ArticleDOI
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
Rigel Suzuki,Daichi Yamasoba,Izumi Kimura,Lei Wang,Mai Kishimoto,Jumpei Ito,Yuhei Morioka,Naganori Nao Nao,Hesham Nasser,Keiya Uriu,Yusuke Kosugi,Masumi Tsuda,Yasuko Orba,Michihito Sasaki,Ryo Shimizu,Ryoko Kawabata,Kumiko Yoshimatsu,Hiroyuki Asakura,Mami Nagashima,Kenji Sadamasu,Kazuhisa Yoshimura,Hirofumi Sawa,Terumasa Ikeda,Takashi Irie,Keita Matsuno,Shinya Tanaka,Takasuke Fukuhara,Kei Sato,The Genotype to Phenotype Japan Consortium +28 more
TL;DR: The emergence of the Omicron variant of SARS-CoV-2 is an urgent global health concern as mentioned in this paper , and statistical modelling suggests that OmicRON has spread more rapidly than the Delta variant in several countries including South Africa.
Journal ArticleDOI
Flavivirus Encephalitis Pathological Aspects of Mouse and Other Animal Models
TL;DR: Among the experimental in vivo models of WNV and JEV infection, mice and other laboratory rodents are the most thoroughly studied and well-characterized systems, having provided data that are important for understanding the infectious process in humans.
Journal ArticleDOI
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
Daichi Yamasoba,Izumi Kimura,Hesham Nasser,Yuhei Morioka,Naganori Nao Nao,Jumpei Ito,Keiya Uriu,Masumi Tsuda,Jiří Zahradník,Kotaro Shirakawa,Rigel Suzuki,Mai Kishimoto,Yusuke Kosugi,Kouji Kobiyama,Teppei Hara,Mako Toyoda,Yurie Tanaka,Erika P. Butlertanaka,Ryo Shimizu,H. Ito,Lei Wang,Yoshitaka Oda,Yasuko Orba,Michihito Sasaki,Kayoko Nagata,Kumiko Yoshimatsu,Hiroyuki Asakura,Mami Nagashima,Kenji Sadamasu,Kazuhisa Yoshimura,Jin Kuramochi,Motoaki Seki,Ryoji Fujiki,Atsushi Kaneda,Tadanaga Shimada,Taka-aki Nakada,Seiichiro Sakao,Takuji Suzuki,Takamasa Ueno,Akifumi Takaori-Kondo,Ken Ishii,Gideon Schreiber,Hirofumi Sawa,Akatsuki Saito,Takashi Irie,Shinya Tanaka,Keita Matsuno,Takasuke Fukuhara,Terumasa Ikeda,Kei Sato +49 more
TL;DR: In this paper , the effective reproduction number of BA.2 is 1.4 times higher than BA.1.1 spike-bearing virus in multiple countries, such as Denmark and the UK.
Journal ArticleDOI
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
Yuto Unoh,Shota Uehara,Kenji Nakahara,Haruaki Nobori,Y. Yamatsu,S. Yamamoto,Y. Maruyama,Yoshiyuki Taoda,Koji Kasamatsu,Takahiro Suto,Kensuke Kouki,Atsufumi Nakahashi,Sho Kawashima,Takao Sanaki,Shinsuke Toba,Kentaro Uemura,Tohru Mizutare,Shigeru Ando,Michihito Sasaki,Yasuko Orba,Hirofumi Sawa,Akihiko Sato,Takafumi Sato,Teruhisa Kato,Yuki Tachibana +24 more
TL;DR: S-217622 exhibited antiviral activity in vitro against current outbreaking SARS-CoV-2 variants and showed favorable pharmacokinetic profiles in vivo for once-daily oral dosing, indicating that this novel noncovalent inhibitor could be a potential oral agent for treating COVID-19.